WHAT IS BENOQUIK MONOBENZONE 20 CREAM
Benoquik cream is made by Quik Pharmaceuticals, also known as Monobenzone 20% is used for depigmentation of the skin as a treatment for widespread vitiligo, a skin condition in which irregular patches of skin, covering about 50% of the body surface, lose colour and become whitened. This is caused by destruction of the pigment-producing cells called melanocytes. Benoquik Monobenzone 20% cream is used as a skin lightener in people with vitiligo, to reduce the color of patches of skin that contain pigment so that they match the areas of skin that have lost color. Decolouration of the skin using Monobenzone cream is permanent and makes the skin sensitive to sunburn during and after treatment.
Monobenzone is the monobenzyl ether of hydroquinone. Monobenzone, applied topically to the skin, is used as a depigmenting agent inhibiting melanin produced by polymerization of oxidation products of tyrosine and dihydroxyphenyl compounds. Monobenzone works by permanently removing color from normal skin located around skin with vitiligo.
Brand names: Agerite, AgeRite, Alba, Alba-Dome, Albaquin, Benoquin, Benoquik, Carmifal, Depigman, Dermochinona, Leucodinine, Monobenzon, Pigmex, Superlite.
Synonyms: Benzoquin, Benzyl hydroquinone, Benzyl p-hydroxyphenyl ether, Hydrochinon monobenzylether, Hydroquinone benzyl ether, Hydroquinone monobenzyl ether, Monobenzona, Monobenzone, Monobenzonum, Monobenzyl ether hydroquinone, Monobenzyl, Ether of Hydroquinone, Monobenzyl hydroquinone, p-Hydroxyphenyl benzyl ether.
HOW DOES BENOQUIK MONOBENZONE 20% CREAM WORK
Benoquik Monobenzone 20% cream contains monobenzone (monobenzyl ether of hyquinone) that works by causing free-radical formation in the skin and this causes destruction of remaining melanocytes. Monobenzone 20% in Benoquik cream also acts by inhibiting the tyrosine enzyme that is involved in the production of melanin, the pigment that gives color to the skin. As the amount of melanin produced decreases the areas of normal skin gradually lighten to match the patches of vitiliginous paler skin.
Monobenzone is a depigmenting agent whose mechanism of action is not fully understood. The topical application of monobenzone in animals, increases the excretion of melanin from the melanocytes. The same action is thought to be responsible for the depigmenting effect of the drug in humans. Monobenzone may cause the destruction of melanocytes and permanent depigmentation. This effect is erratic and may take one to four months to occur while existing melanin is lost with normal sloughing of the stratum corneum. Hyperpigmented skin appears to fade more rapidly than does normal skin, and exposure to sunlight reduces the depigmenting effect of the drug. The histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo; the epidermis is normal except for the absence of identifiable melanocytes.
MAIN INGREDIENTS OF BENOQUIK MONOBENZONE 20% CREAM
Benoquik Monobenzone cream contains the active ingredient monobenzone 20% (mono benzyl ether of hyquinone) in a water-soluble base containing sodium lauryl sulphate, purified water, propylene glycol, cetylalcohol and white wax.
TREATING VITILIGO WITH BENOQUIK MONOBENZONE 20% CREAM
Benoquik Monobenzone 20% cream contains monobenzone a chemical that is used to treat vitiligo, a skin condition in which irregular patches of skin lose color and become whitened, due to destruction of the pigment producing cells called melanocytes. Monobenzone in Benoquik cream is used for depigmentation of the skin and works by causing destruction of remaining melanocytes and by inhibiting the tyrosine enzyme that is involved in the production of melanin, the pigment that gives color to the skin. As the amount of melanin produced decreases, the areas of normal skin gradually lighten to match the patches of vitiliginous paler skin. Decolouration of the skin using Monobenzone cream is permanent and makes the skin sensitive to sunburn.
SIDE EFFECTS OF BENOQUIK MONOBENZONE 20% CREAM
The most commonly reported side effects when taking Benoquik Monobenzone 20% Cream include: sensitivity to sunlight and UV rays, mild skin irritation, itching and redness at the site of application.
DO NOT USE BENOQUIK MONOBENZONE 20% CREAM
You should not use Benoquik 20% Monobenzone Cream if you:
- Allergic to monobenzone or any ingredients in Monobenzone Cream;
- Wanting mild cosmetic bleaching of he skin as this whitening is irreversible;
- Pregnant, or are breastfeeding.
HOW TO USE BENOQUIK MONOBENZONE 20% CREAM
- Benoquik 20% Monobenzone Cream should be applied as a thin layer to normal patches of skin that you want to lighten. Rub in gently and avoid contact with eyes and inside the nose or mouth.
- You should apply your Monobenzone Cream 2 or 3 times daily for up to 5 months as it may take this long to lighten normal skin color to match the vitiliginous paler skin.
- Once you have achieved the skin color that you want, you can continue to use your Monobenzone Cream to maintain this colour by applying up to twice a week.
- If you miss an application procedure of Benoquik Monobenzone 20% Cream take it as soon as you remember, unless it is time to take the next dose, then skip the missed dose. Do not take a double dose.
- Store Benoquik Monobenzone 20% Cream below 25°C in a cool dry place.
Benoquik is a skin cream containing Monobenzone 20% chemical ingredient, which is a topical medication used to remove skin pigmentation in people suffering from the disorder of vitiligo. Vitiligo is a skin condition in which there is a loss of brown color (pigment) from areas of skin, resulting in irregular white patches that feel like normal skin.
Disclaimer: Monobenzone is a potent depigmentation agent. It is neither a skin fairness cream nor mild cosmetic bleach. Monobenzone is not used for treating freckles, sun damage, sun spots, and age spots, skin discoloration caused by hormone medicine, perfumes, pregnancy, or skin trauma.
Prior to starting depigmentation therapy, the person should understand:
- The permanent nature of the treatment;
- The application should always be under strict medical supervision and only by physician/dermatologist advice;
- The need for lifelong, strict sun protection to maintain benefits and reduce the risk of sun damage including skin cancer;
- The slow response to treatment and need for ‘touch–up’ sessions;
- The potentially high cost of treatment;
- Common and uncommon side effects and safety issues;
- Risk that repigmentation will be patchy and incomplete;
- Psychosocial and cultural issues that may arise from change in skin colour.